Amyloid PET in mild cognitive impairment and Alzheimer's disease with BF-227: comparison to FDG-PET.

Journal of Neurology
Katsutoshi FurukawaHiroyuki Arai

Abstract

We recently developed a novel PET tracer, (11)C-labeled 2-(2-[2-dimethylaminothiazol-5-yl]ethenyl)-6-(2-[fluoro]ethoxy)benzoxazole ([(11)C]BF-227), and had success with in vivo detection of amyloid plaques in Alzheimer's disease (AD) brains (Kudo et al. in J Nucl Med 8:553-561, 2007). We applied this tracer to subjects with mild cognitive impairment (MCI) and AD in order to elucidate the status of amyloid plaque deposition in MCI and compared the diagnostic performance of BF-227-PET with that of FDG-PET in AD cases. We studied 12 aged normal (AN) subjects, 15 MCIs and 15 ADs with PET using [(11)C]BF-227. PET images were obtained after administration of BF-227 and the regional standardized uptake value (SUV) and the ratio of regional to cerebellar SUV were calculated as an index of BF-227 binding. AD patients showed increased uptake of [(11)C]BF-227 in the neocortical areas and striatum as well as decreased glucose metabolism in temporoparietal, posterior cingulate and medial temporal areas. MCI subjects showed a significant increase in BF-227 uptake in the neocortical areas similar to AD, and the most significant difference of BF-227 retention was observed in the parietal lobe if its retentions for MCI were compared to those fo...Continue Reading

References

Nov 1, 1993·Neurobiology of Aging·D A BennettR S Wilson
Mar 11, 1999·Annals of Neurology·J L Price, J C Morris
Apr 6, 1999·Archives of Neurology·R C PetersenE Kokmen
Apr 11, 2001·Progress in Neuro-psychopharmacology & Biological Psychiatry·N OkamuraH Sasaki
Aug 30, 2001·Proceedings of the National Academy of Sciences of the United States of America·M J de LeonJ Fowler
May 24, 2003·European Journal of Nuclear Medicine and Molecular Imaging·Alexander DrzezgaAlexander Kurz
Mar 3, 2004·Annals of Neurology·William E KlunkBengt Långström
Aug 25, 2004·Journal of Internal Medicine·R C Petersen
Feb 16, 2005·Archives of Neurology·Chester A MathisSteven T DeKosky
May 10, 2006·Archives of Neurology·Ronald C PetersenEmre Kokmen
May 10, 2006·Archives of Neurology·Gregory A JichaRonald C Petersen
Jun 20, 2006·Journal of Neuropathology and Experimental Neurology·Gregory A JichaJoseph E Parisi
Dec 22, 2006·The New England Journal of Medicine·Gary W SmallJorge R Barrio
Apr 3, 2007·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Yukitsuka KudoHiroyuki Arai
May 15, 2007·Neurobiology of Aging·Anton ForsbergAgneta Nordberg
Jul 17, 2007·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Hiroshi Matsuda
May 1, 2008·The British Journal of Radiology·K HerholzM Jones

❮ Previous
Next ❯

Citations

May 15, 2010·The Tohoku Journal of Experimental Medicine·Hiroyuki AraiYukitsuka Kudo
Jun 15, 2013·Beilstein Journal of Organic Chemistry·Todd J EckroatSylvie Garneau-Tsodikova
Jun 13, 2013·Brain : a Journal of Neurology·Ruiqing NiAgneta Nordberg
May 23, 2014·Brain Connectivity·Hongxiang YaoUNKNOWN Alzheimer’s Disease Neuroimaging Initiative
Jan 19, 2012·European Journal of Nuclear Medicine and Molecular Imaging·V CamusD Guilloteau
Jul 28, 2011·Annals of Nuclear Medicine·Tomohiro KanetaHiroyuki Arai
Nov 1, 2011·Expert Opinion on Medical Diagnostics·Geoffrey A Kerchner
Jan 17, 2016·Ageing Research Reviews·Ikuo TooyamaShigehiro Morikawa
Feb 13, 2015·Rinshō shinkeigaku = Clinical neurology·Katsutoshi FurukawaHiroyuki Arai
Nov 2, 2013·NeuroImage. Clinical·Rik VandenbergheGaël Chételat
Jun 22, 2015·Nuclear Medicine and Biology·Miho ShidaharaKazuhiko Yanai
May 10, 2011·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Jeffrey L Cummings
May 10, 2016·Coronary Artery Disease·Ross FowkesVijay Kunadian
Jan 28, 2021·Seminars in Nuclear Medicine·Aren van WaardeRudi A J O Dierckx
Dec 24, 2020·Seminars in Nuclear Medicine·David J Brooks
Sep 3, 2010·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Ahmadul Kadir, Agneta Nordberg
Jan 8, 2017·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Yuma ArakawaHiroshi Watabe

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.

Alzheimer's Disease: Early Markers

Alzheimer's disease (AD) is a neurodegenerative disease characterized by progressive cognitive and behavioral decline. Targeting markers in the earliest stages of the disease may mitigate the progression of AD. This feed focuses on early diagnosis and markers, as well as environmental, pharmacological, and drug-response biomarkers associated with this disease.

Alzheimer's Disease: Neuroimaging

Neuroimaging can help identify pathological hallmarks of Alzheimer's disease (AD). Here is the latest research on neuroimaging modalities, including magnetic resonance imaging and positron emission tomography, in AD.

Alzheimer's Disease: APP

Amyloid precursor protein (APP) proteolysis is critical for the development of Alzheimer's disease, a neurodegenerative disease associated with accumulation of amyloid plaques in the brain. Here is the latest research on APP and Alzheimer's disease.

Alzheimer's Disease: Amyloid Beta

Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid plaques in the brain; these plaques are comprised of amyloid beta deposits. Here is the latest research in this field.